司库奇尤单抗治疗中重度斑块状银屑病的近期疗效及安全性观察

Short-term efficacy and safety of secukinumab in the treatment of moderate to severe plaque psoriasis:a clinical observation

目的观察司库奇尤单抗治疗中重度斑块状银屑病的近期疗效及安全性。方法2019年6-11月收集就诊于河南省人民医院皮肤科的中重度斑块状银屑病患者36例,给予司库奇尤单抗单药皮下注射治疗,300 mg/次,分别于基线、第1、2、3、4周注射1次,随后每4周1次,分别于第4、8、12周时记录患者银屑病皮损面积和严重度指数(PASI),观察药物不良反应。结果36例患者均接受至少12周的治疗。4周时,8例达PASI75,其中3例达PASI90,1例达PASI100;8周时,26例达PASI75,其中16例达PASI90,4例达PASI100;12周时,32例达PASI75,其中26例达PASI90,8例达PASI100。所有患者均未发生严重感染或恶性肿瘤等严重药物不良反应,1例腹部皮下注射后出现腹痛、腹胀,持续3 d后症状消失;1例患者出现扁桃体炎,之后原有皮损处出现湿疹样改变;1例颈部出现化脓性淋巴结炎。结论司库奇尤单抗治疗中重度斑块状银屑病疗效显著,不良反应较少,是中重度斑块状银屑病患者新的治疗选择之一。

Objective To evaluate the short-term clinical efficacy and safety of secukinumab in the treatment of moderate to severe plaque psoriasis.Methods Thirty-six patients with moderate to severe psoriasis,who visited Department of Dermatology,Henan Provincial People′s Hospital from June 2019 to November 2019,received subcutaneous injection of secukinumab at a dose of 300 mg once a week for 5 weeks,followed by once every 4 weeks.Psoriasis area and severity index(PASI)was recorded at weeks 4,8 and 12,and adverse drug reactions were observed during the treatment.Results All the 36 patients received the treatment for at least 12 weeks.At week 4,8 patients achieved PASI75,including 3 achieving PASI90 and 1 achieving PASI100;at week 8,26 achieved PASI75,of which 16 achieved PASI90 and 4 achieved PASI100;at week 12,32 achieved PASI75,of which 26 achieved PASI90 and 8 achieved PASI100.No patients had serious adverse drug reactions,such as severe infections or malignancies.One patient developed abdominal pain and distension after subcutaneous injection in the abdomen,and the symptoms disappeared after 3 days;1 patient developed tonsillitis followed by eczema-like lesions on the original psoriaitc lesions;suppurative lymphadenitis occurred in the neck of another patient.Conclusion Secukinumab is markedly effective in the treatment of moderate to severe plaque psoriasis with few adverse effects,and is a new treatment option for patients with moderate to severe plaque psoriasis.